ArticlePLoS pathogens2026
Zoological transmission of encephalomyocarditis virus in the United States: Virus evolution, host ecology, and capsid antigenicity derived from an outbreak.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Encephalomyocarditis virus (EMCV): An overlooked threat to primates.PLoS neglected tropical diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encephalomyocarditis virus (EMCV) is a rodent-borne picornavirus that has repeatedly caused severe outbreaks resulting in the deaths of zoo mammals - most notably elephants - for decades. However, within North America, little is known regarding the diversity of EMCV that exists in nature, the reservoir or amplifying hosts important for maintaining the virus, and the epidemiology of zoo-associated outbreaks. This lack of knowledge of the EMCV strains that circulate in North America has impeded a more thorough understanding of how genetic and antigenic variation may affect pathogenicity or potentially vaccine-induced protection from disease. Herein, following a zoological outbreak of EMCV in Florida, we conducted the most comprehensive comparative phylogenomic analysis of virus isolates from fatal zoo animal cases and local rodent species to date, identifying both non-native, invasive rodents and native mice and rat species as potentially important in precipitating and/or maintaining outbreaks, with multiple transmissions to zoo animals. After development of an autogenous vaccine, we investigated the duration and magnitude of neutralizing antibody responses in elephants monthly for multiple years, providing a unique fine-scale, long-term profile of responses to vaccination. To better understand how antigenic variation may affect vaccine-induced protection, we constructed a reverse genetics system to determine the level of cross-protection afforded by autogenous vaccination against capsids derived from various divergent EMCV strains and serotypes. These results provide new advancements in understanding EMCV transmission and antigenicity in North America, which can be used as a foundation to ultimately enable zoos to better protect animals from this important pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.